Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour
Open Access
- 29 March 2005
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 92 (8) , 1574-1580
- https://doi.org/10.1038/sj.bjc.6602478
Abstract
Epigenetic alterations in the 11p15.5 imprinted gene cluster are frequent in human cancers and are associated with disordered imprinting of insulin-like growth factor (IGF)2 and H19. Recently, an imprinted gene cluster at 14q32 has been defined and includes two closely linked but reciprocally imprinted genes, DLK1 and GTL2, that have similarities to IGF2 and H19, respectively. Both GTL2 and H19 are maternally expressed RNAs with no protein product and display paternal allele promoter region methylation, and DLK1 and IGF2 are both paternally expressed. To determine whether methylation alterations within the 14q32 imprinted domain occur in human tumorigenesis, we investigated the status of the GTL2 promoter differentially methylated region (DMR) in 20 neuroblastoma tumours, 20 phaeochromocytomas and, 40 Wilms' tumours. Hypermethylation of the GTL2 promoter DMR was detected in 25% of neuroblastomas, 10% of phaeochromocytoma and 2.5% of Wilms' tumours. Tumours with GTL2 promoter DMR hypermethylation also demonstrated hypermethylation at an upstream intergenic DMR thought to represent a germline imprinting control element. Analysis of neuroblastoma cell lines revealed that GTL2 DMR hypermethylation was associated with transcriptional repression of GTL2. These epigenetic findings are similar to those reported in Wilms' tumours in which H19 repression and DMR hypermethylation is associated with loss of imprinting (LOI, biallelic expression) of IGF2. However, a neuroblastoma cell line with hypermethylation of the GTL2 promoter and intergenic DMR did not show LOI of DLK1 and although treatment with a demethylating agent restored GTL2 expression and reduced DLK1 expression. As described for IGF2/H19, epigenetic changes at DLK1/GTL2 occur in human cancers. However, these changes are not associated with DLK1 LOI highlighting differences in the imprinting control mechanisms operating in the IGF2-H19 and DLK1-GTL2 domains. GTL2 promoter and intergenic DMR hypermethylation is associated with the loss of GTL2 expression and this may contribute to tumorigenesis in a subset of human cancers.Keywords
This publication has 33 references indexed in Scilit:
- Epigenetic detection of human chromosome 14 uniparental disomyHuman Mutation, 2003
- The callipyge locus: evidence for the trans interaction of reciprocally imprinted genesTrends in Genetics, 2003
- High delta‐like 1 expression in a subset of neuroblastoma cell lines corresponds to a differentiated chromaffin cell typeInternational Journal of Cancer, 2003
- Identification of the Single Base Change Causing the Callipyge Muscle Hypertrophy Phenotype, the Only Known Example of Polar Overdominance in MammalsGenome Research, 2002
- Paternal UPD14 is responsible for a distinctive malformation complexAmerican Journal of Medical Genetics, 2002
- dlk Modulates Mitogen-Activated Protein Kinase Signaling to Allow or Prevent DifferentiationExperimental Cell Research, 2002
- Identification of interstitial maternal uniparental disomy (UPD) (14) and complete maternal UPD(20) in a cohort of growth retarded patientsJournal of Medical Genetics, 2001
- SAGE analysis of neuroblastoma reveals a high expression of the human homologue of theDrosophila Delta geneMedical and Pediatric Oncology, 2000
- Epigenetic gene silencing in cancerJournal of Clinical Investigation, 2000
- Tumour-suppressor activity of H19 RNANature, 1993